Quality management systems — applying good distribution practices to the biopharmaceutical supply chain
It is important to ensure compliance with good distribution practice (GDP) throughout the product lifecycle. Failure to incorporate GDP at both pre-and post-market stage may have regulatory implications.
This is member-only content
To read this article, SIGN IN NOW if you are a TOPRA member.
Not a TOPRA member yet?
Join now to get access to:
- Features and specialist articles
- CPD supplements
- Comprehensive archive
Not sure yet? Read one of our free editorials to see what you’re missing out on!
The Organisation for Professionals in Regulatory Affairs
- Issues
- Contact us
- Topics A-Z
- Contributors A-Z
- © 2023 Regulatory Rapporteur